Table 2.
Detailed treatment and prognosis of 2,692 patients with T3N0, T3N1, and T4N0 NPC.
| Items | T3N0, no. (%) | T3N1, no. (%) | T4N0, no. (%) |
|---|---|---|---|
| No. of patients | 401 | 2,098 | 193 |
| Treatment | |||
| CCRT | 274 (68.3) | 1,078 (51.4) | 66 (34.2) |
| IC + CCRT | 127 (31.7) | 1,020 (48.6) | 127 (65.8) |
| CCRT schedule | |||
| 3-weekly | 280 (69.8) | 1,548 (73.8) | 155 (80.3) |
| Weekly | 121 (30.2) | 550 (26.2) | 38 (19.7) |
| Accumulated DDP, mg | 187 | 194 | 188 |
| IC regimen | |||
| TPF | 40 (31.5) | 454 (44.5) | 68 (53.5) |
| PF | 31 (24.4) | 232 (22.7) | 26 (20.5) |
| TP | 56 (44.1) | 334 (32.7) | 33 (26.0) |
| Death (5th yr.) | 16 (4.0) | 128 (6.1) | 23 (11.9) |
| Locoregional relapse (5th yr.) | 15 (3.7) | 123 (5.9) | 20 (10.4) |
| Distant metastasis (5th yr.) | 11 (2.7) | 152 (7.2) | 16 (8.3) |
| Bone | 3 | 18 | 3 |
| Lung | 6 | 40 | 3 |
| Liver | 0 | 35 | 6 |
| Multiple sites | 2 | 45 | 3 |
| Others | 0 | 14 | 1 |
| 3-year OS (%) | 97.3 | 95.7 | 91.2 |
| 5-year OS (%) | 94.3 | 91.9 | 85.2 |
| Ref. | P = 0.116 | P = 0.001 | |
| – | Ref. | P = 0.002 | |
| 3-year FFS (%) | 93.5 | 88.5 | 83.3 |
| 5-year FFS (%) | 90.6 | 84.9 | 76.6 |
| Ref. | P = 0.003 | P < 0.001 | |
| – | Ref. | P = 0.014 | |
| 3-year LRRFS (%) | 96.2 | 94.8 | 91.5 |
| 5-year LRRFS (%) | 95.6 | 93.0 | 85.7 |
| Ref. | P = 0.097 | P = 0.002 | |
| – | Ref. | P = 0.013 | |
| 3-year DMFS (%) | 97.5 | 93.5 | 92.0 |
| 5-year DMFS (%) | 96.8 | 91.6 | 90.6 |
| Ref. | P = 0.002 | P = 0.003 | |
| – | Ref. | P = 0.511 | |
CCRT, concurrent radiochemotherapy; DDP, cisplatin; DMFS, distant metastasis-free survival; FFS, failure-free survival; IC, induction chemotherapy; LRRFS, locoregional relapse-free survival; NPC, nasopharyngeal carcinoma; No., number; OS, overall survival; PF, cisplatin−5-fluorouracil; Ref., reference; TPF, docetaxel–cisplatin−5-fluorouracil; TP, docetaxel–cisplatin; yr., year.